CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders:: High purging efficiency but increased risk of severe infections

被引:19
作者
Altès, A
Sierra, J
Esteve, J
Martin-Henao, G
Marín, P
Sureda, A
Briones, J
Martino, R
Villamor, N
Colomer, D
Carreras, E
Garcia, J
Brunet, S
Montserrat, E
机构
[1] Autonomous Univ Barcelona, Serv Hematol Clin, Hosp Santa Creu & Sant Pau, Clin Hematol Div, Barcelona 08025, Spain
[2] Univ Barcelona, Hosp Clin, IDIBAPS, Inst Clin Malalties Hemato Oncol, E-08007 Barcelona, Spain
[3] Hosp Duran & Reynals, Ctr Transfus & Banc Teixits, Barcelona, Spain
关键词
D O I
10.1016/S0301-472X(02)00828-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The main objective of this work was to decrease the incidence of relapse after autologous stem cell transplantation with a "double purging" procedure. Methods. We used a "positive" (CD34) and "negative" (CD19) double selection method to improve the efficacy of "single purging" of hematopoietic harvests in poor-prognosis lymphoproliferative disorders. All patients included in the study had a positive molecular marker of their disease. Minimal residual disease (MRD) was studied by flow cytometry and PCR techniques during the purging procedure and after transplantation. Results. Twenty-six patients fulfilled entry criteria. Median age of patients was 50 years (range: 33-66); 17 were male and 9 female. Thirteen (50%) of the patients mobilized an adequate number of CD34(+) cells (greater than or equal to3 x 10(6)/kg) to proceed with the double-selection protocol. Twelve of the 13 harvests became PCR negative after purging. Ten patients were grafted with the selected products and all but one engrafted without delay. After a median follow-up of 30 months, 2 of 10 patients suffered a molecular relapse at 7 and 19 months respectively. The earlier relapse was observed in the patient who received a MRD+ product. Only one patient experienced a clinical relapse. Three patients died due to obliterans bronchiolitis, pneumococcal sepsis, and septic shock of unknown origin, respectively, and three others presented life-threatening infections. Conclusion. Therefore, CD34(+)/CD19(+) positive/negative selection is an effective purging approach in patients with chronic lymphoproliferative disorders. This favorable effect is, however, counterbalanced by the high frequency of life-threatening infections. (C) 2002 International Society for Experimental Hematology. Published by Elsevier Science Inc.
引用
收藏
页码:824 / 830
页数:7
相关论文
共 46 条
[31]   Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL) [J].
Martín-Henao, GA ;
Picón, M ;
Limón, A ;
Carmona, M ;
Amill, B ;
Azqueta, C ;
López, R ;
González-Barca, E ;
Grañena, A ;
Brunet, S ;
García, J .
BONE MARROW TRANSPLANTATION, 1999, 23 (06) :579-587
[32]   Isolation of CD34+progenitor cells from peripheral blood by use of an automated immunomagnetic selection system:: factors affecting the results [J].
Martín-Henao, GA ;
Picón, M ;
Amill, B ;
Querol, S ;
González, JR ;
Martínez, C ;
Martino, R ;
Ferrá, C ;
Brunet, S ;
Grañena, A ;
Sierra, J ;
García, J .
TRANSFUSION, 2000, 40 (01) :35-43
[33]  
Martino R, 2000, HAEMATOLOGICA, V85, P1165
[34]  
Montserrat E, 2000, Hematol Cell Ther, V42, P31, DOI 10.1007/s00282-000-0031-2
[35]  
NICOLA MD, 1996, BONE MARROW TRANSPL, V18, P1117
[36]  
Pinyol M, 1996, AM J CLIN PATHOL, V105, P532
[37]  
Reading C L, 1996, J Hematother, V5, P97, DOI 10.1089/scd.1.1996.5.97
[38]  
RILL DR, 1994, BLOOD, V84, P380
[39]   MYELOABLATIVE THERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS CONSOLIDATION THERAPY FOR RECURRENT FOLLICULAR LYMPHOMA [J].
ROHATINER, AZS ;
JOHNSON, PWM ;
PRICE, CGA ;
ARNOTT, SJ ;
AMESS, JAL ;
NORTON, AJ ;
DOREY, E ;
ADAMS, K ;
WHELAN, JS ;
MATTHEWS, J ;
MACCALLUM, PK ;
OZA, AM ;
LISTER, TA .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1177-1184
[40]  
Sambrook J., 1989, MOL CLONING